prednisolone + mycophenolate mofetil

This is a combination therapy consisting of prednisolone, a synthetic glucocorticoid corticosteroid, and mycophenolate mofetil, an immunosuppressive antimetabolite. Prednisolone acts primarily by binding to the glucocorticoid receptor and modulating gene expression to suppress inflammation and immune responses. Mycophenolate mofetil is a prodrug that is rapidly converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo purine synthesis in lymphocytes and thereby inhibiting T- and B-cell proliferation. This combination has been used for various autoimmune diseases (such as lupus nephritis, idiopathic thrombocytopenic purpura [ITP], retroperitoneal fibrosis) as well as in organ transplantation settings to prevent rejection[1][2][3][4][5][7][10]. The regimen leverages the anti-inflammatory effects of prednisolone with the potent immunosuppressive action of mycophenolate mofetil.

Other names

prednisolone and mycophenolate mofetilMMF and prednisolonemycophenolate mofetil and corticosteroid